UMC Utrecht molecular diagnostics spinout Genome Diagnostics has won funding from Ampersand Capital Partners and will work with the private equity firm to spur business growth through activities including M&A.

Osage University Partners has invested in LunaPBC, the public benefit corporation responsible for operating the community-owned LunaDNA genetic and health data collection platform.

UCLA spinout Neural Analytics increased its total funding to $66m as it prepares for further testing of its robotically-assisted brain health monitoring platform.

Therachon, which had raised $100m from investors including Pfizer Ventures and Novo, has agreed to be acquired by Pfizer in a deal that could potentially reach $810m.

GV led a $58.5m round for the heart disease drug developer, which came in the wake of a partnership with another Alphabet subsidiary, Verily.

Pfizer will pay $340m upfront and up to an additional $470m in milestone payments to purchase its portfolio company Therachon, providing an exit to Inserm Transfert Initiative.

Bennett, Coleman & Co has exited online pharmacy Myra and will receive shares in its new owner, Medlife, as part of the acquisition deal.

Texas Medical Center was among the investors in a series A round for the nursing recruitment platform, a graduate of the corporate's accelerator.

Shionogi has participated in an $11m round for flu detection device developer Aillis in connection with the formation of a partnership agreement.

UCL spinout Promethera Biosciences has increased its series D round to $44.4m with a $33.1m Mitsui and Medipal-backed extension, adding to Itochu’s initial investment earlier this year.